We report a case of severe acute thrombocytopenia occurring within days after a cadaveric liver transplant, received from a female patient with aplastic anemia who died of intracranial bleeding. The donor, who was homozygous for the ITGA2B*002 (HPA-3b) gene, had developed human platelet antigen (HPA)-3a antibodies, whereas the recipient was homozygous for the ITGA2B*001 (HPA-3a) gene. Thrombocytopenia responded to an infusion of immunoglobulin G. This is the first report of a passenger lymphocyte syndrome manifesting with thrombocytopenia due to anti-HPA-3a. We review the literature on thrombocytopenia in the setting of PLS and discuss the differential diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/trf.15905 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characteristics of a CCL21-gene modified dendritic cell vaccine utilized for a clinical trial in non-small cell lung cancer.
Mol Cancer Ther
November 2024
University of California, Los Angeles, Los Angeles, CA, United States.
The treatment of non-small cell lung cancer has made major strides with the use of immune checkpoint inhibitors, but there remains a significant need for therapies that can overcome immunotherapy resistance. Dendritic cell (DC) vaccines have been proposed as a therapy that can potentially enhance the antitumor immune response. We have embarked on a phase I clinical trial of a vaccine consisting of monocyte-derived DCs (moDCs) modified to express the chemokine CCL21 (CCL21-DC) given in combination with pembrolizumab.
View Article and Find Full Text PDFCase Report: A case of immune hemolytic anemia after liver transplantation: passenger lymphocyte syndrome is the culprit.
Front Transplant
August 2024
Department of Blood Transfusion, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Article Synopsis
- Passenger lymphocyte syndrome (PLS) typically occurs after solid organ transplants when there’s a minor ABO blood group mismatch, causing donor lymphocytes to attack the recipient’s body.
- A case study is highlighted involving a type A recipient who received a liver from a type O donor, leading to symptoms like jaundice, low hemoglobin, and hemolytic anemia.
- The recipient tested positive for IgG anti-A antibodies, but treatment with immunosuppressive agents and compatible blood transfusions successfully managed her condition without complications.
Enhanced CCR2 expression by ACKR2-deficient NK cells increases tumoricidal cell therapy efficacy.
J Leukoc Biol
November 2024
Chemokine Research Group, School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Sir Graeme Davis Building, 120 University Place, Glasgow G12 8TA, United Kingdom.
Chemokines regulate leukocyte navigation to inflamed sites and specific tissue locales and may therefore be useful for ensuring accurate homing of cell therapeutic products. We, and others, have shown that atypical chemokine receptor 2 (ACKR2)-deficient mice (ACKR2-/-) are protected from metastasis development in cell line and spontaneous mouse models. We have shown that this relates to enhanced CCR2 expression on ACKR2-/- natural killer cells, allowing them to home more effectively to CCR2 ligand-expressing metastatic deposits.
View Article and Find Full Text PDFDonor-derived anti-HLA antibodies in a haploidentical hematopoietic cell transplant recipient shortly after transplant.
Hum Immunol
July 2024
Departments of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. Electronic address:
A pediatric patient with acute myeloid leukemia was referred to our institution for investigational therapy after disease relapse following a mismatched unrelated donor hematopoietic cell transplant (HCT). Prior to second HCT, the patient's serum was negative for antibodies to class I and class II HLA. Eight days after receiving a maternal donor haploidentical transplant, the patient became platelet refractory and highly sensitized to multiple class I HLA.
View Article and Find Full Text PDFImmuno-Hematologic Complexity of ABO-Incompatible Allogeneic HSC Transplantation.
Cells
May 2024
Transfusion Medicine and Stem Cells Unit, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, 00152 Rome, Italy.
ABO incompatibility is not considered a contraindication for hematopoietic stem cell transplantation (HSCT). Approximately 30% of transplants from related donors and up to 50% of transplants from unrelated donors are ABO incompatible. Immuno-hematologic investigations allow to estimate donor/recipient ABO mismatch and anti-A/B isohemagglutinin (IHA) titration in the pre-HSCT phase.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!